Liminatus Pharma, Inc.
LIMN
$6.15
-$0.15-2.38%
NASDAQ
| 12/31/2024 | 03/31/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 167.00K | 96.00K | 47.00K | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 167.00K | 1.71M | 762.00K | ||
| Operating Income | -167.00K | -1.71M | -762.00K | ||
| Income Before Tax | -229.00K | -1.75M | -771.00K | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -229.00K | -1.75M | -771.00K | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -229.00K | -1.75M | -771.00K | ||
| EBIT | -167.00K | -1.71M | -762.00K | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | 0.00 | -0.02 | -0.01 | ||
| Normalized Basic EPS | 0.00 | -0.01 | 0.00 | ||
| EPS Diluted | 0.00 | -0.02 | -0.01 | ||
| Normalized Diluted EPS | 0.00 | -0.01 | 0.00 | ||
| Average Basic Shares Outstanding | 112.22M | 112.22M | 112.33M | ||
| Average Diluted Shares Outstanding | 112.22M | 112.22M | 112.33M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||